期刊文献+

埃索美拉唑在预防老年人阿司匹林相关性溃疡中的作用 被引量:5

The effect of esomeprazole in prevention of peptic ulcers in old patients treated with low-dose of acetylsalicylic acid
下载PDF
导出
摘要 目的观察埃索美拉唑在降低低剂量阿司匹林治疗的老年人中相关溃疡发病率的作用。方法纳入需长期低剂量服用阿司匹林的患者242例,均经快速尿素酶法检测确认无现症幽门螺杆菌感染,符合纳入标准和不具备排除标准的病人,按奇偶数原则和1∶1比例随机分配进入埃索美拉唑组和对照观察组。治疗组晨起餐前口服埃索美拉唑胶囊40mg,每天1次;对照组口服硫糖铝混悬液10ml,每天2次。所有病人观察期限为12周,观察终点后所有纳入研究的病人均需复查胃镜。结果治疗组中无一例出现阿司匹林相关性溃疡及其他上消化道症状,对照组中有11例出现黑便,7例粪便隐血阳性,5例血红蛋白降低(Hb<10g/ml),5例出现消化性溃疡。结论埃索美拉唑40mg/d可以有效降低服用低剂量ASA患者发生内镜下可见消化性溃疡的风险,值得在临床推广。 Objective To determine whether 40 mg of esomeprazole daily reduces the incidence of peptic ulcers over 12 weeks of treatment in patients taking low-dose acetylsalicylic acid (ASA). Methods From January 2010 to December 2012, 242 cases of Helieobacter pylori-negative patients who took a low dose of ASA everyday were included. These patients were randomly divided into esomeprazole group and control group. Esomeprazole group was treated with 40 mg of esomeprazole once a day for 12 weeks, and the control group with placebo. The patients were confirmed peptic ulcer by endoscopy at the end of the treatment. Results After 12 weeks, we found that esomeprazole group significantly reduced the proportion of patients at the risk of peptic ulcers and esomeprazole was generally well tolerated. Conclusion Acidsuppressive treatment with esomeprazole 40 mg a day reduced the occurrence of peptic ulcers in patients at risk for ulcer development who were taking low-dose ASA.
出处 《西部医学》 2013年第2期268-270,273,共4页 Medical Journal of West China
关键词 埃索美拉唑 阿司匹林 老年 溃疡 Esomeprazole Acetylsalicylic acid old patient Peptic ulcer
  • 相关文献

参考文献24

  • 1Baigent C, Blaekwell L, Collins R, etal. Aspirin in the primary and secondary prevention of vascular disease collaborative meta-analysis of individual participant data from randomised trials[J]. Lancet 2009,373 : 1849-1860.
  • 2US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement [J]. Ann Intern Med, 2009, 150: 396-404.
  • 3Hernandez-Diaz S, Garcia Rodriguez LA. Cardioproteetive aspi- rin users and their excess risk of upper gastrointestinal compica- tions[J]. BMC Med, 2006,4 :22.
  • 4Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and inci- dence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin[J]. Aliment Pharmacol Ther, 2005, 22:795-801.
  • 5Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the in- cidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs[J]. Aliment Pharmacol Ther, 2008,28:878-885.
  • 6Sorensen HT, Mellemk.iaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin [J]. Am J Gastroenterol, 2000,95 : 2218-2224.
  • 7Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinua- tion of, low-dose acetylsalicylic acid in patients with cardiovas- cular risk[J]. American Journal of Cardiovascular Drugs, 2010, 10:281-288.
  • 8Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systemat- ic review and recta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coro- nary arterydisease[J]. Eur Heart J, 2006,27:2667-2674.
  • 9Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/ AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines a focused update of the ACCF/ACG/AHA 2008 expert consensus document on re- ducing the gastrointestinal risks of antiplatelet therapy and NSAID use[J]. Am J Gastroenterol, 2010,105:2533-2549.
  • 10张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民.幽门螺杆菌共识意见(2003·安徽桐城)[J].中华消化杂志,2004,24(2):126-127. 被引量:439

二级参考文献19

  • 1Malfertheiner P, Megraud F, O'Morain C, et al. European Helicobacter Pylori Study Group(EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther, 2002,16:167-180.
  • 2Patrono C,Bachmann F,Baigent C,et al.European Society of Cardiology.Expert consensus document on the use of antiplatelet agents.The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.Eur Heart J,2004,25:166-181.
  • 3Eagle KA,Guyton RA,Davidoff R,et al.American College of Cardiology.American Heart Association Task Force on Practice Guidelines.American Society for Thoracic Surgery and the Society of Thoracic Surgeons.ACC/AHA 2004 guideline update for coronary artery bypass graft surgery:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).Circulation,2004,110:1168-1176.
  • 4Stein PD,Alpert JS,Bussey HI,et al.Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest,2001,119:2205-2275.
  • 5Chen ZM,Jiang LX,Chen YP,et al.COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial.Lancet,2005,366:1607-1621.
  • 6Patrono C,Coller B,FitzGerald GA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126(3 Suppl):234S-264S.
  • 7Pearson TA,Blair SN,Daniels SR,et al.AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke:2002 Update:Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases.American Heart Association Science Advisory and Coordinating Committee.Circulation,2002,106:388-391.
  • 8Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med,2005,352:1293-1304.
  • 9Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86.
  • 10Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med,2001,345:494-502.

共引文献701

同被引文献25

  • 1李华茵,何礼贤,胡必杰,王葆青,陈雪华,马伟.呼吸机相关肺炎内源性感染途径的分子流行病学研究[J].中华医院感染学杂志,2004,14(2):121-125. 被引量:153
  • 2湛先保,李兆申,程能能,杜奕奇,邹多武,尹宁,龚燕芳.埃索美拉唑对健康志愿者抑制胃泌酸的药效学研究[J].中华消化杂志,2004,24(12):711-714. 被引量:21
  • 3钟英强,许哲,郭佳念.埃索美拉唑和氟哌噻吨美利曲辛治疗伴有抑郁或焦虑的非糜烂性胃食管反流病[J].中华消化杂志,2006,26(7):444-447. 被引量:53
  • 4中华医学杂志编辑委员会.应激性溃疡防治建议[J].中华医学杂志,2002,82:1000-1001.
  • 5Muscedere J,Dodek P, Keenan S,et al.Comprehensive ev- idence-based clinical prtactice guidelines for ventilator-associated pneumonia:diagnosis and treatment[J].J Crit Care, 2008,23( 1 ) : 138-147.
  • 6R Gillespie.Prevention and management of ventilator-as- sociated pneumonia-the Care Bundle approach [J].SAJCC, 2009,25 (2) : 44-52.
  • 7Scheiman JM,Devereaux PJ,Herlitz J,et al.Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid:a randomised,controlled trial(OBERON)[J].Heart,2011,97:797-802.
  • 8Lai KC,Lam SK,Chu KM,et al.Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use[J].N Engl J Med,2002,346(26):2033-2038.
  • 9Yeomans N,Lanas A,Labenz J,et al.Efficacy of esomeprazole(20 mg once daily)for reducing the risk of gastrointestinal ulcers associated with continuous use of low-dose aspirin[J].Am J Gastroenterol,2008,103(10):2465-2473.
  • 10Ng FH,Wong SY,Lam KF,et al.Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions[J].Gastroenterology,2010,138:82-88.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部